R
ecessive dystrophic epidermolysis bullosa (RDEB) is caused by loss-offunction mutations in the COL7A1 gene that result in reduced levels or complete absence of type VII collagen (C7). The disease is characterized by progressively worsening blistering, inflammation, pain, scarring, and contractures. C7 is an extracellular matrix protein that homopolymerizes into anchoring fibrils (AFs) and plays a critical role in adherence of skin layers at the dermal-epidermal junction (DEJ) in cutaneous and mucosal membranes. Multiple cell types can express C7-keratinocytes, fibroblasts (FBs), mesenchymal stromal/stem cells (MSCs, Figure 1 ), perhaps even hematopoietic cells-but are the cell types functionally and qualitatively similar or equal? In several methodical and incisive studies, injections of allogeneic FBs or MSCs have been used for wound healing in individuals with RDEB, [1] [2] [3] [4] [5] [6] and the study by Kühl and colleagues reported in this issue adds to our knowledge regarding the use of MSCs as medications for wound healing in RDEB. 7 Kühl et al. 7 found that human MSCs express C7 in vitro at approximately the same level as FBs. When injected into the skin of a murine RDEB model (these RDEB "hypomorphic" mice express C7 at approximately 10% of wild-type levels), human MSCs deposited human C7 at the DEJ in a dose-dependent manner. Although xenografted MSCs did not proliferate, they persisted for about 1 month; human C7 decreased proportionately but was detectable up to 3 months after injections. Resistance to injury (measured by putting adhesive tape on shaved skin and ripping it off) was improved, and rudimentary AFs (C7 homotrimers) increased in number along the DEJ. There were no significant local side effects and no systemic immune reactivity to human C7. In fact, whereas wounds generated in wild-type mice did not benefit from MSC injections, the naturally occurring wounds in RDEB mice showed faster wound closure after MSC local treatment than when injected with vehicle alone. Crucially, this productive tissue repair reaction may not have been solely a consequence of C7 expression but may also have been due to a synergy with the immune-modulatory and reparative functions of MSCs.
This work demonstrates the possibility of an unlikely symbiosis between two essentially unrelated medical fields: hematology and dermatology. MSCs, routinely derived from hematopoietic organs such as bone marrow or umbilical cord blood, 8 are shown here to merge with the goals of dermatologists to alleviate blistering in this prototypical genodermatosis. They are clearly connected in development; hematopoietic cells, connective tissue stromal cells, and dermis are all derived from mesoderm, one of the primary germ layers of the embryo. Therefore, thinking in the new conceptual space of mesoderm derivatives and their impact on skin (mesodermatology) might facilitate a thoughtful examination of MSCs and other bone marrow-derived cells in skin disorders.
This functional link between bone marrow and skin has a long history. In 1876 Julius Cohnheim argued for a bold new way of understanding tissue boundaries and hypothesized that cells mediating post-traumatic fibrosis in skin and other organs might originate in blood and bone marrow. 9 In [13] [14] [15] [16] and then to use bone marrow or umbilical cord blood for hematopoietic cell transplantation to change generalized severe RDEB from a fatal to a treatable, controllable, and eventually curable disease. 17, 18 The next challenge is to separate cells used as clinical-grade MSCs (fundamentally changed by the artificial environment of cell culture) from their physiological counterparts, the resident MSCs (such as pericytes and other components of tissue niches), 19 where MSC identity is defined by local microenvironment and their fate is directed by extracellular matrix and neighboring cells. If we can combine the current clinical insights on the use of MSCs with new tools to explore them in their physiological circumstances, we will unveil not only their functional diversity but possible ways to manipulate them, including niche-directed therapies. As both skin and bone marrow stromal cells and their niches have been studied extensively, we should be able to integrate this knowledge into a mesodermatological concept of MSCs. This, in turn, should lead to its practical translation into an array of bone marrow-derived therapies to enhance regeneration and healing in RDEB, other genodermatoses, and other extracellular matrix disorders. more complex picture emerged as more data were uncovered on the heterogeneity, clonality, self-renewal, and functional diversity of these cells in both fresh and cultured forms.
Almost in contrast to the complexity of the basic biology of MSCs, the relative ease with which they can be obtained, cultured, and prepared under good manufacturing practices for human use has led to a remarkable number of clinical trials. MSCs have been used clinically for two decades, and MSC infusions have shown clinical benefit in some applications, such as connective tissue injury or graft-versus-host disease (the main immune complication of allogeneic hematopoietic cell transplantation). For other indications, however, their value is less clear. Nevertheless, through application of MSCs in different injuries and disease states, several concepts have emerged: (i) MSCs are multifunctional; (ii) the capacity of MSCs to contribute to the musculoskeletal system and to modulate immune and inflammatory responses can be separated; (iii) the magnitude and quality of donor MSC engagement depends on recipient factors; (iv) MSCs interact with their cellular partners directly, by cell-to-cell contact, or indirectly, by short-range or longrange signals (free protein mediators or exosomes 12 ); and (v) the changeability of MSCs, their conceptual resistance to traditional hierarchical thinking, and their versatility in adopting various cell fates such as mesenchymal-to-epithelial transition, may be an advantage in clinical applications. It is possible that MSCs are a mobile link via blood circulation and a modular link among stromal components of various organs. They can provide homeostasis and tissue maintenance in health, can mediate productive repair in injury states, and can also drive pathology, such as in the microenvironment of some cancers.
Kühl et al. show here that skin injection of MSCs can improve wound healing in a murine model of RDEB. 7 One of the key insights of this work is that the MSCs are multitalented: in addition to secreting C7, they are able to mobilize myofibroblasts, ameliorate skin inflammation, and increase skin stability. Their
